AU2005210084B2 - Combination of anticholinergics and inhibitors of phosphodiesterase type 4 for the treatment of respiratory diseases - Google Patents
Combination of anticholinergics and inhibitors of phosphodiesterase type 4 for the treatment of respiratory diseases Download PDFInfo
- Publication number
- AU2005210084B2 AU2005210084B2 AU2005210084A AU2005210084A AU2005210084B2 AU 2005210084 B2 AU2005210084 B2 AU 2005210084B2 AU 2005210084 A AU2005210084 A AU 2005210084A AU 2005210084 A AU2005210084 A AU 2005210084A AU 2005210084 B2 AU2005210084 B2 AU 2005210084B2
- Authority
- AU
- Australia
- Prior art keywords
- physiologically acceptable
- acceptable salts
- glycopyrrolate
- roflumilast
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 208000023504 respiratory system disease Diseases 0.000 title claims abstract description 18
- 238000011282 treatment Methods 0.000 title claims description 25
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 title claims description 21
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 title claims description 21
- 239000003112 inhibitor Substances 0.000 title claims description 16
- 239000000812 cholinergic antagonist Substances 0.000 title description 10
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 title description 7
- 229940015042 glycopyrrolate Drugs 0.000 claims abstract description 66
- MNDBXUUTURYVHR-UHFFFAOYSA-N roflumilast Chemical compound FC(F)OC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OCC1CC1 MNDBXUUTURYVHR-UHFFFAOYSA-N 0.000 claims abstract description 48
- 229960002586 roflumilast Drugs 0.000 claims abstract description 48
- 208000006673 asthma Diseases 0.000 claims abstract description 46
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims abstract description 43
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims abstract description 38
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 claims abstract description 30
- 239000000203 mixture Substances 0.000 claims abstract description 14
- 150000003839 salts Chemical class 0.000 claims description 43
- HJORMJIFDVBMOB-UHFFFAOYSA-N rolipram Chemical compound COC1=CC=C(C2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-UHFFFAOYSA-N 0.000 claims description 22
- 229950005741 rolipram Drugs 0.000 claims description 22
- VPNYRYCIDCJBOM-UHFFFAOYSA-M Glycopyrronium bromide Chemical compound [Br-].C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 VPNYRYCIDCJBOM-UHFFFAOYSA-M 0.000 claims description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 10
- 239000011885 synergistic combination Substances 0.000 claims description 10
- 206010020751 Hypersensitivity Diseases 0.000 claims description 9
- 230000007815 allergy Effects 0.000 claims description 9
- 208000030603 inherited susceptibility to asthma Diseases 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 7
- 241000283073 Equus caballus Species 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 239000013543 active substance Substances 0.000 claims description 4
- 230000002195 synergetic effect Effects 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 239000000443 aerosol Substances 0.000 claims description 2
- 239000003380 propellant Substances 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims 2
- -1 adjuncts Substances 0.000 claims 2
- 241000948268 Meda Species 0.000 claims 1
- 239000006185 dispersion Substances 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 230000001078 anti-cholinergic effect Effects 0.000 abstract description 12
- DPHDSIQHVGSITN-UHFFFAOYSA-N n-(3,5-dichloropyridin-4-yl)-2-[1-[(4-fluorophenyl)methyl]-5-hydroxyindol-3-yl]-2-oxoacetamide Chemical compound C1=C(C(=O)C(=O)NC=2C(=CN=CC=2Cl)Cl)C2=CC(O)=CC=C2N1CC1=CC=C(F)C=C1 DPHDSIQHVGSITN-UHFFFAOYSA-N 0.000 abstract description 9
- 230000004054 inflammatory process Effects 0.000 abstract description 8
- 229940124630 bronchodilator Drugs 0.000 abstract description 7
- 206010061218 Inflammation Diseases 0.000 abstract description 6
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 abstract description 4
- 239000000168 bronchodilator agent Substances 0.000 abstract description 3
- 238000009472 formulation Methods 0.000 abstract description 3
- 238000011321 prophylaxis Methods 0.000 abstract description 2
- 238000002636 symptomatic treatment Methods 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 22
- 239000003814 drug Substances 0.000 description 20
- 229940079593 drug Drugs 0.000 description 19
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 17
- 150000001875 compounds Chemical class 0.000 description 14
- 239000002158 endotoxin Substances 0.000 description 13
- 229920006008 lipopolysaccharide Polymers 0.000 description 13
- 102100040247 Tumor necrosis factor Human genes 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 208000037883 airway inflammation Diseases 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 239000000556 agonist Substances 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 210000000440 neutrophil Anatomy 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- 241000283086 Equidae Species 0.000 description 5
- 210000000038 chest Anatomy 0.000 description 5
- 210000001616 monocyte Anatomy 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 4
- 101100296720 Dictyostelium discoideum Pde4 gene Proteins 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 101100082610 Plasmodium falciparum (isolate 3D7) PDEdelta gene Proteins 0.000 description 4
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000003092 anti-cytokine Effects 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 238000007726 management method Methods 0.000 description 4
- 230000008506 pathogenesis Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 229940110309 tiotropium Drugs 0.000 description 4
- LERNTVKEWCAPOY-DZZGSBJMSA-N tiotropium Chemical compound O([C@H]1C[C@@H]2[N+]([C@H](C1)[C@@H]1[C@H]2O1)(C)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 LERNTVKEWCAPOY-DZZGSBJMSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 108700012920 TNF Proteins 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 210000003979 eosinophil Anatomy 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 239000003862 glucocorticoid Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 210000003097 mucus Anatomy 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 229940037128 systemic glucocorticoids Drugs 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 208000036065 Airway Remodeling Diseases 0.000 description 2
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 108010044467 Isoenzymes Proteins 0.000 description 2
- 208000019693 Lung disease Diseases 0.000 description 2
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 2
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 239000013566 allergen Substances 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000001022 anti-muscarinic effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000007883 bronchodilation Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 208000023819 chronic asthma Diseases 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 238000000432 density-gradient centrifugation Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000003630 histaminocyte Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 229960001888 ipratropium Drugs 0.000 description 2
- OEXHQOGQTVQTAT-JRNQLAHRSA-N ipratropium Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 OEXHQOGQTVQTAT-JRNQLAHRSA-N 0.000 description 2
- 230000005923 long-lasting effect Effects 0.000 description 2
- 230000004199 lung function Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000011533 pre-incubation Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000003118 sandwich ELISA Methods 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000013595 supernatant sample Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- GWNVDXQDILPJIG-CCHJCNDSSA-N 11-trans-Leukotriene C4 Chemical compound CCCCC\C=C/C\C=C\C=C\C=C\[C@H]([C@@H](O)CCCC(O)=O)SC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O GWNVDXQDILPJIG-CCHJCNDSSA-N 0.000 description 1
- LSLYOANBFKQKPT-DIFFPNOSSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(O)C=C(O)C=1)C1=CC=C(O)C=C1 LSLYOANBFKQKPT-DIFFPNOSSA-N 0.000 description 1
- 208000000884 Airway Obstruction Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 206010014950 Eosinophilia Diseases 0.000 description 1
- 102100023688 Eotaxin Human genes 0.000 description 1
- 101710139422 Eotaxin Proteins 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 241000208125 Nicotiana Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 206010030111 Oedema mucosal Diseases 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000036428 airway hyperreactivity Effects 0.000 description 1
- 210000005091 airway smooth muscle Anatomy 0.000 description 1
- 210000005057 airway smooth muscle cell Anatomy 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000011861 anti-inflammatory therapy Methods 0.000 description 1
- 230000001262 anti-secretory effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
- 229940092705 beclomethasone Drugs 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 230000007885 bronchoconstriction Effects 0.000 description 1
- 230000003182 bronchodilatating effect Effects 0.000 description 1
- 238000011685 brown norway rat Methods 0.000 description 1
- 230000011496 cAMP-mediated signaling Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000034196 cell chemotaxis Effects 0.000 description 1
- 230000008614 cellular interaction Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 229960001022 fenoterol Drugs 0.000 description 1
- 229960002848 formoterol Drugs 0.000 description 1
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000007233 immunological mechanism Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000037456 inflammatory mechanism Effects 0.000 description 1
- 229940125369 inhaled corticosteroids Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000010983 kinetics study Methods 0.000 description 1
- 229960001021 lactose monohydrate Drugs 0.000 description 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 231100000516 lung damage Toxicity 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004001 molecular interaction Effects 0.000 description 1
- 239000003149 muscarinic antagonist Substances 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000001129 nonadrenergic effect Effects 0.000 description 1
- 230000002536 noncholinergic effect Effects 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 230000008756 pathogenetic mechanism Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000009325 pulmonary function Effects 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 230000004648 relaxation of smooth muscle Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- 229960004017 salmeterol Drugs 0.000 description 1
- 230000009291 secondary effect Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000005586 smoking cessation Effects 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Otolaryngology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54195504P | 2004-02-06 | 2004-02-06 | |
| US60/541,955 | 2004-02-06 | ||
| PCT/EP2005/000651 WO2005074982A2 (en) | 2004-02-06 | 2005-01-24 | Combination of anticholinergics and inhibitors of phosphodiesterase type 4 for the treatment of respiratory diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2005210084A1 AU2005210084A1 (en) | 2005-08-18 |
| AU2005210084B2 true AU2005210084B2 (en) | 2010-06-24 |
Family
ID=34837532
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2005210084A Ceased AU2005210084B2 (en) | 2004-02-06 | 2005-01-24 | Combination of anticholinergics and inhibitors of phosphodiesterase type 4 for the treatment of respiratory diseases |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US20050175547A1 (enExample) |
| EP (1) | EP1713471B1 (enExample) |
| JP (1) | JP4700014B2 (enExample) |
| CN (2) | CN100512813C (enExample) |
| AT (1) | ATE541570T1 (enExample) |
| AU (1) | AU2005210084B2 (enExample) |
| CA (1) | CA2550848C (enExample) |
| CY (1) | CY1112968T1 (enExample) |
| DK (1) | DK1713471T3 (enExample) |
| ES (1) | ES2381116T3 (enExample) |
| HR (1) | HRP20120286T1 (enExample) |
| NO (1) | NO337023B1 (enExample) |
| NZ (1) | NZ548301A (enExample) |
| PL (1) | PL1713471T3 (enExample) |
| PT (1) | PT1713471E (enExample) |
| RU (1) | RU2437658C2 (enExample) |
| SI (1) | SI1713471T1 (enExample) |
| WO (1) | WO2005074982A2 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
| JP2007524699A (ja) * | 2004-02-27 | 2007-08-30 | アルタナ ファルマ アクチエンゲゼルシャフト | ロフルミラストとグリコピロニウムとの組合せ物 |
| ES2257152B1 (es) * | 2004-05-31 | 2007-07-01 | Laboratorios Almirall S.A. | Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos. |
| EP1616567A1 (en) * | 2004-07-16 | 2006-01-18 | Boehringer Ingelheim Pharma GmbH & Co.KG | Medicaments for inhalation comprising PDE IV inhibitors and glycopyrrolate salts |
| US20090221664A1 (en) * | 2005-10-19 | 2009-09-03 | Abhijit Ray | Pharmaceutical compositions of muscarinic receptor antagonists |
| EP1894568A1 (en) * | 2006-08-31 | 2008-03-05 | Novartis AG | Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases |
| MX2010004529A (es) * | 2007-10-25 | 2010-05-10 | Merck Frosst Canada Ltd | Composiciones de inhalacion que comprenden acido montelukast y un inhibidor de fosfodiesterasa-4 o un corticoesteroide inhalado. |
| NZ587561A (en) * | 2008-02-26 | 2012-10-26 | Elevation Pharmaceuticals Inc | Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations (an muscarinic antagnoist) |
| US20100055045A1 (en) | 2008-02-26 | 2010-03-04 | William Gerhart | Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations |
| EP2100598A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
| EP2100599A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
| EP2510928A1 (en) | 2011-04-15 | 2012-10-17 | Almirall, S.A. | Aclidinium for use in improving the quality of sleep in respiratory patients |
| CN110403922A (zh) * | 2013-01-28 | 2019-11-05 | 理森制药股份公司 | 通过吸入罗氟司特n-氧化物治疗自身免疫、呼吸和/或炎性病症的方法 |
| PT2968313T (pt) * | 2013-03-15 | 2018-02-21 | Verona Pharma Plc | Combinação de fármacos |
| TW201542207A (zh) * | 2013-10-03 | 2015-11-16 | Otsuka Pharma Co Ltd | 嚴重氣喘治療劑 |
| CN104586841A (zh) * | 2013-10-30 | 2015-05-06 | 中国药科大学 | (3r,2’r)-格隆溴铵作为m3毒蕈碱性受体拮抗剂在制药中的用途 |
| CN104800192A (zh) * | 2014-01-27 | 2015-07-29 | 成都英诺新科技有限公司 | 一种罗氟司特吸入粉雾剂及制备方法 |
| RU2691110C2 (ru) * | 2017-11-20 | 2019-06-11 | Федеральное государственное бюджетное учреждение науки Сибирский федеральный научный центр агробиотехнологий Российской академии наук (СФНЦА РАН) | Препарат для лечения заболеваний дыхательных путей у лошадей и способ его применения |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001076575A2 (en) * | 2000-04-07 | 2001-10-18 | Arakis Ltd. | The treatment of respiratory diseases |
| WO2002096423A2 (en) * | 2001-05-25 | 2002-12-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Combination of a pde4 inhibitor and tiotropium or derivate thereof for treating obstructive airways |
| WO2002096463A1 (en) * | 2001-05-25 | 2002-12-05 | Pfizer Inc. | A pde 4 inhibitor and an anti-cholinergic agent in combination for treating obstructive airways diseases |
| WO2003011274A2 (en) * | 2001-07-27 | 2003-02-13 | Glaxo Group Limited | Use of a pde4 inhibitor in combination with an anticholinergic agent for the treatment of pulmonary disease such as asthma |
| AU2002257587B2 (en) * | 2001-03-07 | 2007-05-10 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Novel medicament compositions on the basis of anticholinergics and PDE IV inhibitors |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI0706513T1 (en) * | 1993-07-02 | 2002-10-31 | Altana Pharma Ag | Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors |
| WO1998000016A1 (en) * | 1996-07-01 | 1998-01-08 | Sepracor, Inc. | Methods and compositions for treating urinary incontinence using enantiomerically enriched (r,r)-glycopyrrolate |
| US6384038B1 (en) * | 1998-04-14 | 2002-05-07 | Sepracor Inc. | Methods and compositions using cetirizine in combination with leukotriene inhibitors or decongestants |
| US6402285B1 (en) * | 1998-05-29 | 2002-06-11 | Citizen Watch Co., Ltd. | Method of subjecting ink jet printer to preuse treatment |
| DK1102579T3 (da) * | 1998-08-04 | 2003-07-14 | Jago Res Ag | Medicinske aerosolformuleringer |
| RU2221552C2 (ru) * | 1998-11-13 | 2004-01-20 | Джаго Рисерч Аг | Сухой порошок для ингаляции |
| DE19921693A1 (de) * | 1999-05-12 | 2000-11-16 | Boehringer Ingelheim Pharma | Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika |
| US6086914A (en) * | 1999-03-12 | 2000-07-11 | Weinstein; Robert E. | Nonsedating formulations for allergic rhinitis which possess antihistaminic and anticholinergic activity |
| US20040002548A1 (en) * | 1999-05-12 | 2004-01-01 | Boehringer Ingelheim Pharma Kg | Medicament compositions containing anticholinergically-effective compounds and betamimetics |
| US20040028958A1 (en) * | 2002-06-18 | 2004-02-12 | Total Innovative Manufacturing Llc | Recyclable fire-resistant moldable batt and panels formed therefrom |
| DE19961300A1 (de) * | 1999-12-18 | 2001-06-21 | Asta Medica Ag | Vorratssystem für Arzneimittel in Pulverform und damit ausgestatteter Inhalator |
| DE10007203A1 (de) * | 2000-02-17 | 2001-08-23 | Asta Medica Ag | Neue Kombination nichtsedierender Antihistaminika mit Substanzen, die die Leukotrienwirkung beeinflussen, zur Behandlung der Rhinitis/Konjunktivitis |
| GB0009583D0 (en) * | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Respiratory formulations |
| GB0029903D0 (en) * | 2000-12-07 | 2001-01-24 | Arakis Ltd | Use of anti-muscarinic agents |
| US20040101483A1 (en) | 2001-03-30 | 2004-05-27 | Rudi Muller-Walz | Medical aerosol formulations |
| US6667344B2 (en) * | 2001-04-17 | 2003-12-23 | Dey, L.P. | Bronchodilating compositions and methods |
| US7258118B2 (en) * | 2002-01-24 | 2007-08-21 | Sofotec Gmbh & Co, Kg | Pharmaceutical powder cartridge, and inhaler equipped with same |
| DE10230769A1 (de) * | 2002-07-09 | 2004-01-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Arzneimittelkompositionen auf der Basis neuer Anticholinergika und PDE-IV-Inhibitoren |
| US20040038958A1 (en) * | 2002-07-11 | 2004-02-26 | Chris Rundfeldt | Topical treatment of skin diseases |
| UA82323C2 (uk) * | 2002-08-09 | 2008-04-10 | Меда Фарма Гмбх & Ко. Кг | Нова комбінація глюкокортикоїду та pde-інгібітору для лікування респіраторних захворювань, алергічних захворювань, астми та хронічних обструктивних легеневих захворювань |
| US20040053902A1 (en) * | 2002-09-13 | 2004-03-18 | Smith C. Steven | Novel composition and method for treatment of upper respiratory conditions |
| MXPA05010160A (es) * | 2003-03-28 | 2005-11-16 | Altana Pharma Ag | Combinacion sinergistica que comprende roflumilast y un agente anticolinergico seleccionado a partir de sales de ipratropio, oxitropio y tiotropio para el tratamiento de enfermedades respiratorias. |
| WO2004084897A1 (en) | 2003-03-28 | 2004-10-07 | Altana Pharma Ag | Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases |
| CN100520419C (zh) | 2003-07-11 | 2009-07-29 | Nxp股份有限公司 | 改进的频率确定 |
-
2005
- 2005-01-24 RU RU2006132040/15A patent/RU2437658C2/ru not_active Application Discontinuation
- 2005-01-24 NZ NZ548301A patent/NZ548301A/en not_active IP Right Cessation
- 2005-01-24 PL PL05701141T patent/PL1713471T3/pl unknown
- 2005-01-24 HR HR20120286T patent/HRP20120286T1/hr unknown
- 2005-01-24 AU AU2005210084A patent/AU2005210084B2/en not_active Ceased
- 2005-01-24 CA CA2550848A patent/CA2550848C/en not_active Expired - Fee Related
- 2005-01-24 DK DK05701141.3T patent/DK1713471T3/da active
- 2005-01-24 EP EP05701141A patent/EP1713471B1/en not_active Expired - Lifetime
- 2005-01-24 SI SI200531513T patent/SI1713471T1/sl unknown
- 2005-01-24 PT PT05701141T patent/PT1713471E/pt unknown
- 2005-01-24 CN CNB200580002345XA patent/CN100512813C/zh not_active Expired - Fee Related
- 2005-01-24 JP JP2006551762A patent/JP4700014B2/ja not_active Expired - Fee Related
- 2005-01-24 ES ES05701141T patent/ES2381116T3/es not_active Expired - Lifetime
- 2005-01-24 CN CN200910133531A patent/CN101518532A/zh active Pending
- 2005-01-24 AT AT05701141T patent/ATE541570T1/de active
- 2005-01-24 WO PCT/EP2005/000651 patent/WO2005074982A2/en not_active Ceased
- 2005-02-07 US US11/051,463 patent/US20050175547A1/en not_active Abandoned
-
2006
- 2006-07-13 US US11/485,486 patent/US20060251589A1/en not_active Abandoned
- 2006-08-31 NO NO20063880A patent/NO337023B1/no not_active IP Right Cessation
-
2009
- 2009-02-03 US US12/365,003 patent/US8097605B2/en not_active Expired - Lifetime
-
2012
- 2012-03-29 CY CY20121100323T patent/CY1112968T1/el unknown
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001076575A2 (en) * | 2000-04-07 | 2001-10-18 | Arakis Ltd. | The treatment of respiratory diseases |
| AU2002257587B2 (en) * | 2001-03-07 | 2007-05-10 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Novel medicament compositions on the basis of anticholinergics and PDE IV inhibitors |
| WO2002096423A2 (en) * | 2001-05-25 | 2002-12-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Combination of a pde4 inhibitor and tiotropium or derivate thereof for treating obstructive airways |
| WO2002096463A1 (en) * | 2001-05-25 | 2002-12-05 | Pfizer Inc. | A pde 4 inhibitor and an anti-cholinergic agent in combination for treating obstructive airways diseases |
| WO2003011274A2 (en) * | 2001-07-27 | 2003-02-13 | Glaxo Group Limited | Use of a pde4 inhibitor in combination with an anticholinergic agent for the treatment of pulmonary disease such as asthma |
Also Published As
| Publication number | Publication date |
|---|---|
| NO337023B1 (no) | 2015-12-28 |
| NO20063880L (no) | 2006-11-02 |
| WO2005074982A3 (en) | 2006-04-06 |
| RU2006132040A (ru) | 2008-03-20 |
| EP1713471A2 (en) | 2006-10-25 |
| HRP20120286T1 (hr) | 2012-04-30 |
| JP2007520507A (ja) | 2007-07-26 |
| US8097605B2 (en) | 2012-01-17 |
| AU2005210084A1 (en) | 2005-08-18 |
| NZ548301A (en) | 2010-07-30 |
| CN101518532A (zh) | 2009-09-02 |
| WO2005074982A2 (en) | 2005-08-18 |
| CA2550848C (en) | 2013-02-26 |
| CY1112968T1 (el) | 2016-04-13 |
| RU2437658C2 (ru) | 2011-12-27 |
| US20050175547A1 (en) | 2005-08-11 |
| US20090136429A1 (en) | 2009-05-28 |
| DK1713471T3 (da) | 2012-05-14 |
| ES2381116T3 (es) | 2012-05-23 |
| PL1713471T3 (pl) | 2012-06-29 |
| JP4700014B2 (ja) | 2011-06-15 |
| SI1713471T1 (sl) | 2012-07-31 |
| CA2550848A1 (en) | 2005-08-18 |
| US20060251589A1 (en) | 2006-11-09 |
| CN100512813C (zh) | 2009-07-15 |
| ATE541570T1 (de) | 2012-02-15 |
| HK1096311A1 (zh) | 2007-06-01 |
| EP1713471B1 (en) | 2012-01-18 |
| CN1909899A (zh) | 2007-02-07 |
| PT1713471E (pt) | 2012-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8097605B2 (en) | Combination of anticholinergics and inhibitors of phosphodiesterase type 4 for the treatment of respiratory disease | |
| US8518918B2 (en) | Combination of anticholinergics, β2-adrenoceptor agonists, antileukotrienes (leukotriene receptor antagonists), glucocorticoids and/or phosphodiesterase 4 inhibitors for the treatment of inflammatory diseases | |
| US10537550B2 (en) | Methods of treating underlying inflammation from COPD or asthma | |
| Tenor et al. | Pharmacology, clinical efficacy, and tolerability of phosphodiesterase-4 inhibitors: impact of human pharmacokinetics | |
| MXPA06008937A (en) | Combination of anticholinergics and inhibitors of phosphodiesterase type 4 for the treatment of respiratory diseases | |
| HK1096311B (en) | Combination of anticholinergics and inhibitors of phosphodiesterase type 4 for the treatment of respiratory diseases | |
| HK1136487A (en) | Combination of anticholinergics and inhibitors of phosphodiesterase type 4 for the treatment of respiratory diseases | |
| AU2012200449B2 (en) | Combination of anticholinergics, glucocorticoids, beta2-agonists, PDE4 inhibitor and antileukotriene for the treatment of inflammatory diseases | |
| HK1123497B (en) | Combination of anticholinergics, glucocorticoids, beta2-agonists, pde4 inhibitor and antileukotriene for the treatment of inflammatory diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |